ibrutinib,rituximab
abbvie,janssen
[]
#ash22 results from the randomized triangle trial by the european mcl network. a new standard for first-line therapy. presented by prof. martin dreyling and 
LMU University Hospital Munich IMPRESSUM: https://t.co/ahNblC09Ru